AstraZeneca Pharma gets DCGI nod to the market asthma drug ...Middle East

Drug firm AstraZeneca Pharma on Monday said it has received marketing authorization from the Drug Controller General of India for Benralizumab solution, indicated as an add-on maintenance treatment for severe asthma. AstraZeneca Pharma India Ltd has received import and market permission in Form CT-20 (marketing authorization) from the Drugs Controller General of India for Benralizumab 30mg/ml solution for injection (Fasenra), the drug firm said in a regulatory filing. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

Hence then, the article about astrazeneca pharma gets dcgi nod to the market asthma drug was published today ( Monday 21/12/2020 - 08:30 AM ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AstraZeneca Pharma gets DCGI nod to the market asthma drug )

Also on site :

• Voices: ‘It helps willpower, it doesn’t replace it’: Readers divided as Wegovy pill arrives in UK
• NYCHA’s $465,000-a-year plumber is just a taste of its massive dysfunction
• An 18% City Council pay hike is a middle finger to NYC voters